



**Vaccines and Global Health: The Week in Review**  
**16 May 2020 :: Number 552**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday evening at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full-text searching of over 9,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

**Contents** *[click on link below to move to associated content]*

A. [Milestones :: Perspectives :: Featured Journal Content](#)

B. [Emergencies](#)

C. [WHO; CDC \[U.S., Africa, China\]](#)

D. [Announcements](#)

E. [Journal Watch](#)

F. [Media Watch](#)



## ***Milestones :: Perspectives :: Research***

### **Seventy-third World Health Assembly**

#WHA73

*Due to the current COVID-19 pandemic, the 73rd World Health Assembly will be virtual. The agenda has been reduced to fit into two days, **starting on Monday 18 May and concluding no later on Tuesday 19 May.** [Watch live](#)*

#### **Main documents**

[A73/1](#) Provisional agenda

The programme will cover:

- :: Opening of the Health Assembly by WHA 72 President
- :: Election of the President and five Vice-Presidents
- :: Presidential address
- :: Statements by invited speakers
- :: Address by the Director-General (on COVID-19 pandemic response)
- :: Statements by Heads of delegation on COVID-19 pandemic
- :: EB: election
- :: Closure/suspension (The WHA will consider suspending and reconvening later in the year to consider the remaining items on the agenda)

[A73/4](#) Consolidated report by the Director-General

[A73/5](#) Consolidated report by the Director-General

[A73/6](#)

Global vaccine action plan  
Defeating meningitis by 2030  
Meningitis prevention and control

[A73/7](#)

Global vaccine action plan  
Draft immunization vision and strategy: "Immunization Agenda 2030"

[A73/8](#)

Neglected tropical diseases  
Draft road map for neglected tropical diseases 2021–2030

[A73/9](#)

WHO Global Code of Practice on the International Recruitment of Health Personnel  
Report of the WHO Expert Advisory Group on the Relevance and Effectiveness of the WHO  
Global Code of Practice on the International Recruitment of Health Personnel

[A73/12](#)

Poliomyelitis  
Polio eradication

[A73/13](#)

Poliomyelitis  
Polio transition planning and polio post-certification

[A73/14](#)

International Health Regulations (2005)  
Annual report on the implementation of the International Health Regulations (2005)

[A73/16](#)

Programme budget 2020–2021  
WHO results framework: an update

[A73/20](#)

Evaluation of the election of the Director-General of the World Health Organization

[A73/21](#)

Human resources: annual report

[A73/22](#)

Amendments to the Staff Regulations and Staff Rules

[A73/23](#)

Appointment of representatives to the WHO Staff Pension Committee

[A73/30](#)

Collaboration within the United Nations system and with other intergovernmental organizations  
Reform of the United Nations development system and implications for WHO

[A73/32](#)

Progress reports

.....  
.....

**COVID-19 : Joint Statement**

**Uniting behind a people's vaccine against COVID-19**

14 May 2020

Humanity today, in all its fragility, is searching for an effective and safe vaccine against COVID-19. It is our best hope of putting a stop to this painful global pandemic.

**We are calling on Health Ministers at the World Health Assembly to rally behind a people's vaccine against this disease urgently. Governments and international partners must unite around a global guarantee which ensures that, when a safe and effective vaccine is developed, it is produced rapidly at scale and made available for all people, in all countries, free of charge. The same applies for all treatments, diagnostics, and other technologies for COVID-19.**

We recognize that many countries and international organizations are making progress towards this goal, cooperating multilaterally on research and development, funding and access, including the welcome \$8 billion pledged on 4th May. Thanks to tireless public and private sector efforts and billions of dollars of publicly-financed research, many vaccine candidates are proceeding with unprecedented speed and several have begun clinical trials.

Our world will only be safer once everyone can benefit from the science and access a vaccine - and that is a political challenge. The World Health Assembly must forge a global agreement that ensures rapid universal access to quality-assured vaccines and treatments with need prioritized above the ability to pay.

**It is time for Health Ministers to renew the commitments made at the founding of the World Health Organization, where all states agreed to deliver the “the highest attainable standard of health as a fundamental right of every human being”.**

Now is not the time to allow the interests of the wealthiest corporations and governments to be placed before the universal need to save lives, or to leave this massive and moral task to market forces. Access to vaccines and treatments as global public goods are in the interests of all humanity. We cannot afford for monopolies, crude competition and near-sighted nationalism to stand in the way.

We must heed the warning that “Those who do not remember the past are doomed to repeat it.” We must learn the painful lessons from a history of unequal access in dealing with disease such as HIV and Ebola. But we must also remember the ground-breaking victories of health movements, including AIDS activists and advocates who fought for access to affordable medicines for all.

Applying both sets of lessons, we call for a global agreement on COVID-19 vaccines, diagnostics and treatments – implemented under the leadership of the World Health Organization – that:

**[1] Ensures mandatory worldwide sharing of all COVID-19 related knowledge, data and technologies with a pool of COVID-19 licenses freely available to all countries.**

Countries should be empowered and enabled to make full use of agreed safeguards and flexibilities in the WTO Doha Declaration on the TRIPS Agreement and Public Health to protect access to medicines for all.

**[2] Establishes a global and equitable rapid manufacturing and distribution plan – that is fully-funded by rich nations – for the vaccine and all COVID-19 products and technologies that guarantees transparent ‘at true cost-prices’ and supplies according to need.**

Action must start urgently to massively build capacity worldwide to manufacture billions of vaccine doses and to recruit and train the millions of paid and protected health workers needed to deliver them.

**[3] Guarantees COVID-19 vaccines, diagnostics, tests and treatments are provided free of charge to everyone, everywhere.**

Access needs to be prioritized first for front-line workers, the most vulnerable people, and for poor countries with the least capacity to save lives.

In doing so, no one can be left behind. **Transparent democratic governance must be set in place by the WHO, inclusive of independent expertise and civil society partners, which is essential to lock-in accountability for this agreement.**

In doing so, we also recognize the urgent need to reform and strengthen public health systems worldwide, removing all barriers so that rich and poor alike can access the health care, technologies and medicines they need, free at the point of need.

Only a people's vaccine – with equality and solidarity at its core – can protect all of humanity and get our societies safely running again. A bold international agreement cannot wait.

*Signed,*

Nana Addo Dankwa Akufo-Addo – President of the Republic of Ghana

Imran Khan - Prime Minister of the Islamic Republic of Pakistan

Cyril Ramaphosa - President of the Republic of South Africa and Chairperson of the African Union..

*[Fifty+ signatories; Full list at title link above]*

.....  
.....

## **COVID-19 :: Clinical Trials Coordination**

### **[Press release: International coordination needed to encourage conduct of large, decision-relevant COVID-19 clinical trials](#)**

European Medicines Agency Last updated: 15/05/2020

Regulators are highlighting the need for a comprehensive international coordination mechanism to allow the conduct of adequately powered, randomised controlled trials, which can generate sound evidence on the effects of therapeutics or vaccines against COVID-19. This follows a call made by EMA's Human Medicines Committee (CHMP) for the research community to pool resources into large, well-designed, multi-arm clinical trials to determine which investigational or repurposed medicines would be safe and effective for the treatment or prevention of COVID-19.

Although the scientific community has responded to the COVID-19 challenge in an unprecedented manner, there are concerns about the growing number of COVID-19 stand-alone clinical trials with a small number of participants and observational studies, which might not generate the data required for regulatory decision-making.

In an article published today in Clinical Pharmacology & Therapeutics, EMA authors have therefore set out concrete actions that stakeholders involved with COVID-19 clinical trials should take to generate the type of conclusive evidence needed to enable rapid development and approval of potential treatments and vaccines against COVID-19. These include: research community to consider whether their planned trial can become part of a larger platform;

:: developers of COVID-19 treatments to seek interactions with regulators as early as possible; support well-established public or private consortia to ramp up their activities and take on a wider role in the management of trials;

:: regulatory flexibility in clinical trial management to address challenges arising from the COVID-19 pandemic, while ensuring a high level of quality, efficacy and safety of medicines;

:: ethics committees to ensure that the benefits of conducting a stand-alone clinical trial for COVID-19 outweighs risks and burdens to the participants;  
:: establish infrastructure to support clinical trial conduct;  
:: umbrella patient organisations and learned societies to use their influence to encourage clinical trial coordination.

Medicine regulatory authorities worldwide are cooperating under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA) with the aim of expediting and streamlining the development of COVID-19 vaccines and treatments. In a series of ICMRA meetings on COVID-19 held in March and April 2020, they have exchanged information about regulatory issues, including prioritisation of COVID-19 clinical trials, and sought alignment in their approaches to enhance the efficiency and effectiveness of regulatory decision-making during the current pandemic.

The article entitled 'Clinical trials for Covid-19: can we better use the short window of opportunity?' is available through open access in Clinical Pharmacology & Therapeutics.

.....  
.....

## Featured Journal Content

### Science

11 May 2020:

eabc5312 DOI: 10.1126/science.abc5312

*Policy Forum*

#### [A strategic approach to COVID-19 vaccine R&D](#)

By Lawrence Corey<sup>[1,2](#)</sup>, John R. Mascola<sup>[3](#)</sup>, Anthony S. Fauci<sup>[4](#)</sup>, Francis S. Collins<sup>[5](#)</sup>

*Abstract*

*A public-private partnership and platform for harmonized clinical trials aims to accelerate licensure and distribution.*

*[Initial text]*

There is an unprecedented need to manufacture and distribute enough safe and effective vaccine to immunize an extraordinarily large number of individuals in order to protect the entire global community from the continued threat of morbidity and mortality from severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2). The global need for vaccine and the wide geographic diversity of the pandemic require more than one effective vaccine approach. Collaboration will be essential among biotechnology and pharmaceutical companies, many of which are bringing forward a variety of vaccine approaches (<sup>[1](#)</sup>). The full development pathway for an effective vaccine for SARS-CoV-2 will require that industry, government, and academia collaborate in unprecedented ways, each adding their individual strengths. We discuss one such collaborative program that has recently emerged: the ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines) public-private partnership. Spearheaded by the U.S. National Institutes of Health (NIH), this effort brings together the strengths of all sectors at this time of global urgency. We further discuss a collaborative platform for conducting harmonized, randomized controlled vaccine efficacy trials. This mechanism aims to generate essential safety and efficacy data for several candidate vaccines in parallel, so as to accelerate the licensure and distribution of multiple vaccine platforms and vaccines to protect against COVID-19 (coronavirus disease 2019)...



## EMERGENCIES

### Coronavirus [COVID-19]

*Public Health Emergency of International Concern (PHEIC)*

#### **Editor's Note:**

We certainly recognize the velocity of global developments in the COVID-19 pandemic. While we have concentrated the most current key reports just below, COVID-19 announcements, analysis and commentary will be found throughout this issue, in all sections.

Beyond the considerable continuing coverage in the global general media, the WHO's authoritative guidance is available here:

**:: Daily WHO situation reports** here: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>

**:: WHO Coronavirus disease (COVID-2019) daily press briefings** here: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/press-briefings>

#### **Situation report - 117** [WHO]

Novel Coronavirus (COVID-19)

16 May 2020

*[Excerpts]*

#### **Situation in numbers (by WHO Region)**

*Total (new cases in last 24 hours)*

<b>Globally</b>	4 425 485 cases (86 827)	302 059 deaths (4 940)
Africa	54 461 cases (2 271)	1 667 deaths (44)
Americas	1 909 483 cases (45 015)	115 057 deaths (3 123)
Eastern Mediterranean	315 668 cases (10 479)	9 701 deaths (143)
Europe	1 848 445 cases (22 150)	164 723 deaths (1 446)
South-East Asia	127 995 cases (5 741)	4 201 deaths (151)
Western Pacific	166 721 cases (1 171)	6 697 deaths (33)

#### **HIGHLIGHTS**

:: WHO has published a new scientific brief on "[Multisystem inflammatory syndrome in children and adolescents with COVID-19](#)", given the reported clusters of children and adolescents who require admission to intensive care units with a multisystem inflammatory condition. There is an urgent need for collecting standardized data describing epidemiology, clinical presentations, severity, and outcomes.

:: WHO Director-General Dr Tedros, in his media briefing yesterday, highlighted the need to "unleash the full power of science, to deliver innovations that are scalable, usable, and benefit everyone, everywhere, at the same time".

:: WHO has published new guidance on "[Cleaning and disinfection of environmental surfaces in the context of COVID-19](#)", intended for healthcare professionals, public health professionals and health authorities that are developing and implementing cleaning and disinfection policies and standard operating procedures.

:: WHO and UNICEF have published a document on frequently asked questions (FAQs) about immunization in the context of the COVID-19 pandemic. These FAQs accompany WHO's [Guiding principles for immunization activities during the COVID-19 pandemic.](#)"

.....  
.....

## **Emergencies**

### **Ebola – DRC+**

*Public Health Emergency of International Concern (PHEIC)*

#### **Ebola Outbreak in DRC 92: 12 May 2020**

*[Excerpts]*

##### ***Situation Update***

From 4 to 10 May 2020, there have been no new confirmed cases of Ebola virus disease (EVD) reported in Democratic Republic of the Congo. Since the resurgence of the outbreak on 10 April 2020, seven confirmed cases have been reported from Kasanga, Malepe and Kansulinzuli Health Areas in Beni Health Zone...

##### ***Conclusion***

The cluster of EVD cases that emerged in April 2020 highlights the importance of heightened vigilance for the response in the face of significant challenges around community engagement, access to affected areas, ongoing insecurity, and limited response capacity due to other local and global emergencies. New cases are expected among contacts of recent cases reported in Beni Health Zone. The origin of this recent chain of transmission should continue to be investigated in order to prepare for future similar events. It is crucial to detect, isolate, test and treat new suspected cases as early as possible in order to improve outcome of cases and break the chain of transmission. Strong coordination and communication among partners, authorities and affected communities is essential, as well as continued support for and engagement with EVD survivors.

.....  
.....

## **Emergencies**

### **POLIO**

*Public Health Emergency of International Concern (PHEIC)*

#### **Polio this week as of 13 May 2020**

:: The GPEI has released an [updated guide](#) that synthesizes and references new evidence and recommendations to help ensure continuity of the programme's operations in the context of the COVID-19 pandemic.

:: In the context of the COVID-19 pandemic – certain countries are facing stock-outs of bi-valent Oral Polio Vaccine (bOPV) for their essential immunization services. To address this, the program has circulated a [Statement](#) on the use of bOPV supplied for Supplementary Immunization Activities (SIAs) in routine immunization activities.



:: The WHA will take place on 18-19 May over video conference. While discussions will focus on COVID-19 and items essential for business continuity, reports on [Polio Eradication](#) and [Polio Transition](#) have been made available to Member States. The polio report provides an overview of the epidemiological situation and highlights the Executive Board (EB) decision adopted earlier this year on the [Strategy for Control of cVDPV2 2020–2021](#), including the roll-out of nOPV2 under Emergency Use Listing (EUL).

***Summary of new viruses this week (AFP cases and ES positives):***

- :: **Afghanistan:** one WPV1 case
- :: **Pakistan:** four WPV1 cases, 13 WPV1 positive environmental samples
- :: **Somalia:** three cVDPV2 positive environmental samples
- :: **Chad:** two cVDPV2 cases
- :: **Cote d'Ivoire:** One cVDPV2 case

.....

**[WHO Grade 3 Emergencies](#)** [to 16 May 2020]

**Democratic Republic of the Congo**

- :: Ebola Outbreak in DRC 92: 12 May 2020

Nigeria - *No new digest announcements identified*  
Somalia - *No new digest announcements identified*  
South Sudan - *No new digest announcements identified*  
Syrian Arab Republic - *No new digest announcements identified*  
Yemen - *No new digest announcements identified*

.....

**[WHO Grade 2 Emergencies](#)** [to 16 May 2020]

Angola - *No new digest announcements identified*  
Afghanistan - *No new digest announcements identified*  
Burkina Faso [in French] - *No new digest announcements identified*  
Burundi - *No new digest announcements identified*  
Cameroon - *No new digest announcements identified*  
Central African Republic - *No new digest announcements identified*  
Ethiopia - *No new digest announcements identified*  
Iran - *No new digest announcements identified*  
Iraq - *No new digest announcements identified*  
Libya - *No new digest announcements identified*  
Malawi - *No new digest announcements identified*  
Measles in Europe - *No new digest announcements identified*  
MERS-CoV - *No new digest announcements identified*  
Myanmar - *No new digest announcements identified*  
Niger - *No new digest announcements identified*  
occupied Palestinian territory - *No new digest announcements identified*  
Sudan - *No new digest announcements identified*  
Ukraine - *No new digest announcements identified*  
Zimbabwe - *No new digest announcements identified*

.....

### **WHO Grade 1 Emergencies** [to 16 May 2020]

Chad - *No new digest announcements identified*

Djibouti - *No new digest announcements identified*

Kenya - *No new digest announcements identified*

Mali - *No new digest announcements identified*

Namibia - viral hepatitis - *No new digest announcements identified*

Tanzania - *No new digest announcements identified*

.....

.....

### **UN OCHA – L3 Emergencies**

*The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system's classification for the response to the most severe, large-scale humanitarian crises.*

#### **Syrian Arab Republic**

:: Recent Developments in Northwest Syria - Situation Report No. 14 - As of 15 May 2020

Yemen - *No new digest announcements identified*

.....

### **UN OCHA – Corporate Emergencies**

When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.

#### **CYCLONE IDAI and Kenneth**

:: 12 May 2020 Somalia: Flooding displaces thousands from their homes amid COVID-19

:: 12 May 2019 Southern Africa: Tropical Cyclone Kenneth Flash Update No. 12 (12 May 2019)

:: 14 May 2020 Zimbabwe Situation Report, 14 May 2020

:: EBOLA OUTBREAK IN THE DRC - *No new digest announcements identified*

.....

.....

### **WHO & Regional Offices** [to 16 May 2020]

*News release*

#### **WHO and Costa Rica preview technology pooling initiative to ensure access to COVID-19 health products for all**

Geneva, 15 May 2020 – Presidents Carlos Alvarado Quesada of Costa Rica and Sebastián Piñera of Chile joined WHO Director-General Dr Tedros Adhanom Ghebreyesus today to announce progress on a technology platform that aims to lift access barriers to effective vaccines, medicines and other health products against COVID-19. Costa Rica proposed the idea at the beginning of the COVID-19 outbreak and several countries are now backing the proposal.

"Our proposal relies on solidarity," said President Alvarado of Costa Rica. "It's a Solidarity call to action to Member States, to academia, to companies, research institutions and cooperation agencies, based on global social responsibility, on a voluntary basis, promoting more global nonexclusive voluntary licensing."

"We need to unleash the full power of science, without caveats or restrictions, to deliver innovations that are scalable, usable, and benefit everyone, everywhere, at the same time," said WHO Director-General Dr Tedros Adhanom Ghebreyesus...

14 May 2020 *News release*

**[Substantial investment needed to avert mental health crisis](#)**

13 May 2020 *News release*

**[WHO: People living longer and healthier lives but COVID-19 threatens to throw progress off track](#)**

13 May 2020 *News release*

**[Launch of the WHO Academy and the WHO Info mobile applications](#)**

11 May 2020 *News release*

**[ECOSOC Informal Briefing on 'Joining Forces: Effective Policy Solutions for Covid-19 Response'](#)**

.....

**[Weekly Epidemiological Record, 15 May 2020, vol. 95, 20 \(pp. 209–228\)](#)**

Dracunculiasis eradication: global surveillance summary, 2019

.....

## **WHO Regional Offices**

*Selected Press Releases, Announcements*

### **WHO African Region AFRO**

:: [COVID-19 could deepen food insecurity, malnutrition in Africa](#) 14 May 2020

:: [Nigeria drives routine immunization amid COVID-19](#) 14 May 2020

:: [Ghana bolsters medicines regulatory system, guarantees product quality](#) 13 May 2020

### **WHO Region of the Americas PAHO**

*No new digest content identified.*

### **WHO South-East Asia Region SEARO**

:: [Local epidemiology should guide focused action in 'new normal' COVID-19 world](#) 15 May 2020

### **WHO European Region EURO**

:: [COVID-19: WHO joins forces with young Global Shapers to disseminate health advice](#) 15-05-2020

:: [Behavioural insights are valuable to inform the planning of appropriate pandemic response measures](#) 14-05-2020

- :: [Polish medics bring Italian COVID-19 experience to Kyrgyzstan with WHO support](#) 13-05-2020
- :: [Bulgaria launches new national programme amid pandemic on violence against women and children](#) 13-05-2020
- :: [New WHO resource on enhancing competencies of primary care nurses](#) 12-05-2020

### **WHO Eastern Mediterranean Region EMRO**

- :: [Yemen faces unprecedented risk as COVID-19 starts to spread](#) 13 May 2020
- :: [WHO supports accelerated response efforts for contact tracing in Somalia](#) 11 May 2020
- :: [Migrants face COVID-19 discrimination in Yemen](#) 10 May 2020

### **WHO Western Pacific Region**

*No new digest content identified.*

.....  
.....

**CDC/ACIP** [to 16 May 2020]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

*Latest News Releases*

**[Media Statement from Dr. Robert Redfield, CDC Director; Dr. Steve Hahn, FDA Commissioner; and Dr. Anthony Fauci, NIAID Director](#)** Tuesday, May 12, 2020

The Centers for Disease Control and Prevention (CDC) and the U.S. Department of Homeland Security (DHS) have together determined that government entities working in support of the COVID-19 response efforts are providing essential services and the current guidelines for critical infrastructure workers apply. Therefore, providing that they are asymptomatic, screened, and monitored for fever and other symptoms, wear a face covering, and maintain a distance of at least six feet from others, Drs. Redfield, Hahn, and Fauci can and will participate in meetings on the White House complex when their attendance is needed.

### **[MMWR News Synopsis Friday, May 15, 2020](#)**

[Survival and HIV-Free Survival Among Children Aged  \$\leq 3\$  Years — Eight Sub-Saharan African Countries, 2015–2017](#)

[COVID-19 in Correctional and Detention Facilities — United States, February–April 2020 \(Early release May 6, 2020\)](#)

[Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration — United States, 2020 \(Early release May 8, 2020\)](#)

[Public Health Response to COVID-19 Cases in Correctional and Detention Facilities — Louisiana, March–April 2020 \(Early release May 8, 2020\)](#)

[Identification and Monitoring of International Travelers During the Initial Phase of an Outbreak of COVID-19 — California, February 3–March 17, 2020 \(Early release May 11, 2020\)](#)

[Preliminary Estimate of Excess Mortality During the COVID-19 Outbreak — New York City, March 11–May 2, 2020 \(Early release May 11, 2020\)](#)

High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice — Skagit County, Washington, March 2020 (Early release May 12, 2020)

.....

**Africa CDC** [to 16 May 2020]

<http://www.africacdc.org/>

*News*

[\*\*African researchers lead scientific coalition developing surveillance system for detecting emerging pandemics in real-time\*\*](#)

11 May 2020

.....

**China CDC**

<http://www.chinacdc.cn/en/>

*No new digest content identified.*

**National Health Commission of the People's Republic of China**

<http://en.nhc.gov.cn/>

*News*

[\*\*May 16: Daily briefing on novel coronavirus cases in China\*\*](#)

2020-05-16

[\*\*Xi calls for vigilance to combat virus\*\*](#)

2020-05-15

[\*\*Chinese mainland's asymptomatic COVID-19 cases drop in past 10 days: official\*\*](#)

2020-05-15

[\*\*5 vaccines in China set to finish phase 2 trials in July\*\*](#)

2020-05-15

China now has five vaccines, one vector and four inactivated, that have entered the first two phases of clinical trials in China, a senior scientist said on May 15. Vaccine recipients in phase II trials have reported no major adverse effects, and these vaccines are set to complete their phase II trials in July.

"As of today, vaccine development is generally progressing smoothly," Zeng Yixin, deputy director of the National Health Commission, said in a news briefing on Friday.

Zeng said some vaccine candidates are conducting phase I and II clinical trials concurrently in China, which is considered "an innovation" in the emergency approval mechanism of the National Medical Products Administration.

Right now, 2,575 volunteers in total have been administered the five vaccines, including 539 volunteers for phase I trials, Zeng said. "We have gained preliminary data for phase I trials on the vaccines' safety and ability to create protective antibodies."

The phase II trials, which enrolled 2,036 volunteers, aim to further evaluate the vaccines' safety and potency. "Some volunteers are taking more than one dose now, and relevant research is ongoing," he said.

"We have not recorded any major adverse effects for volunteers in these trials," he said. "If everything goes according to plan, these projects would finish their phase II trial in July."...

### **Best efforts made in early study of virus spread, says health authority**

2020-05-15

.....  
.....

### **Announcements**

**Paul G. Allen Frontiers Group** [to 16 May 2020]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 16 May 2020]

<http://www.gatesfoundation.org/Media-Center/Press-Releases>

*Press Releases and Statements*

*No new digest content identified.*

**Bill & Melinda Gates Medical Research Institute** [to 16 May 2020]

<https://www.gatesmri.org/>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*No new digest content identified.*

**CARB-X** [to 16 May 2020]

<https://carb-x.org/>

*CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.*

05.11.2020 |

### **CARB-X funds 60th project – \$220M invested so far, plus millions more if milestones are met**

CARB-X announced its 60th award today, representing more than \$220 million invested since CARB-X was established in 2016 to support the early development of innovative products to fight drug resistance.

05.11.2020 |

### **CARB-X awards Day Zero Diagnostics \$6.2M to develop a new test that would diagnose deadly superbug infections faster and determine what antibiotic would be most effective**

CARB-X is awarding Day Zero Diagnostics, based in Boston, up to US\$6.2 million in non-dilutive funding to develop a diagnostic system that could diagnose bacterial infections more quickly – within hours rather than days - and show physicians which antibiotics are most likely to effectively treat the infection. The innovative technology combines whole-genome sequencing and machine learning to identify the species of a pathogen and its drug-resistance profile without the need for culture, providing physicians with vital information to speed the appropriate treatment of serious drug-resistant bacterial infections in hours rather than days.

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 16 May 2020]

<http://cepi.net/>

*Latest News*

**[CEPI extends collaboration with Novavax to advance development and manufacture of COVID-19 vaccine](#)**

11 May 2020

**Clinton Health Access Initiative, Inc. (CHAI)** [to 16 May 2020]

<https://clintonhealthaccess.org/>

*News & Press Releases*

*No new digest content identified.*

**EDCTP** [to 16 May 2020]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*Latest news*

*No new digest content identified.*

**Emory Vaccine Center** [to 16 May 2020]

<http://www.vaccines.emory.edu/>

*[Undated]*

*No new digest content identified.*

**European Medicines Agency** [to 16 May 2020]

<http://www.ema.europa.eu/ema/>

*News & Press Releases*

**[EU actions to support availability of medicines during COVID-19 pandemic – update #6](#)**

Press release 15/05/2020

The EU Executive Steering Group on Shortages of Medicines Caused by Major Events held a virtual meeting on 13 May 2020. Participation to the meeting of the steering group was extended to all the heads of the national competent authorities (NCAs) of the EU Member

States to discuss the measures taken by EU authorities to ensure the continued availability of medicines in Europe during the ongoing COVID-19 pandemic...

**[Press release: International coordination needed to encourage conduct of large, decision-relevant COVID-19 clinical trials](#)**

Last updated: 15/05/2020

*[See Perspectives above for detail]*

**[News: EMA recommends expanding remdesivir compassionate use to patients not on mechanical ventilation](#)**

Last updated: 11/05/2020

**European Vaccine Initiative** [to 16 May 2020]

<http://www.euvaccine.eu/news-events>

*Latest News*

*No new digest content identified.*

**FDA** [to 16 May 2020]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

*Press Announcements*

**[May 16, 2020 - Coronavirus \(COVID-19\) Update: FDA Authorizes First Standalone At-Home Sample Collection Kit That Can Be Used With Certain Authorized Tests](#)**

The U.S. Food and Drug Administration has authorized an at-home sample collection kit that can then be sent to specified laboratories for COVID-19 diagnostic testing. Specifically, the FDA issued an emergency use authorization (EUA) to Everlywell, Inc. for the Everlywell COVID-19 Test Home Collection Kit. Everlywell's kit is authorized to be used by individuals at home who have been screened using an online questionnaire that is reviewed by a health care provider...

[May 15, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup May 15, 2020](#)

[May 14, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup May 14, 2020](#)

**[May 14, 2020 - Coronavirus \(COVID-19\) Update: FDA Informs Public About Possible Accuracy Concerns with Abbott ID NOW Point-of-Care Test](#)**

Today, the U.S. Food and Drug Administration is alerting the public to early data that suggest potential inaccurate results from using the Abbott ID NOW point-of-care test to diagnose COVID-19. Specifically, the test may return false negative results.

"We are still evaluating the information about inaccurate results and are in direct communications with Abbott about this important issue. We will continue to study the data available and are working with the company to create additional mechanisms for studying the test. This test can still be used and can correctly identify many positive cases in minutes. Negative results may need to be confirmed with a high-sensitivity authorized molecular test," said Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA's Center for Devices and Radiological Health...

[May 13, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup May 13, 2020](#)



[May 12, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup May 12, 2020](#)

[May 11, 2020 - Coronavirus \(COVID-19\) Update: \*\*FDA Takes New Actions to Accelerate Development of Novel Prevention, Treatment Options for COVID-19\*\*](#)

Today, the U.S. Food and Drug Administration took important actions to help accelerate the development of prevention and treatment options for COVID-19 by providing new guidance with recommendations for innovators and researchers conducting work in this area. These guidance documents aim to make the process for submitting applications to initiate studies for new drugs and biological products more efficient and outline recommendations for ways to design clinical trials to evaluate safety and effectiveness of these medical products for COVID-19...

**Fondation Merieux** [to 16 May 2020]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 16 May 2020]

<https://www.gavi.org/>

*News releases*

12 May 2020

[\*\*Canada commits CAD 600 million to Gavi\*\*](#)

11 May 2020

[\*\*Spain pledges new support to Gavi\*\*](#)

**GHIT Fund** [to 16 May 2020]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that*

*No new digest content identified.*

**Global Fund** [to 16 May 2020]

<https://www.theglobalfund.org/en/news/>

*Sourcing & Management of Health Products*

[\*\*COVID-19 Diagnostics Procurement through the Global Fund\*\*](#)

15 May 2020

*News*

[\*\*Global Fund Board Members Unite to Fight\*\*](#)

15 May 2020

*Voices*

[\*\*On the Front Lines: Responding to COVID-19\*\*](#)

15 May 2020

*Voices*

**[Amid COVID-19, Communities Continue Fight against Other Pandemics](#)**

12 May 2020

*Voices*

**[Protecting Mothers and Babies from HIV during the COVID-19 Pandemic](#)**

12 May 2020

**Hilleman Laboratories** [to 16 May 2020]

<http://www.hillemanlabs.org/>

*No new digest content identified.*

**Human Vaccines Project** [to 16 May 2020]

<http://www.humanvaccinesproject.org/media/press-releases/>

*HVP COVID Report* May 13, 2020

**[Human Challenges to Accelerate SARS-CoV-2 Vaccine Development](#)**

By Stanley A. Plotkin, MD

Emeritus Professor of Pediatrics

University of Pennsylvania

Vaxconsult

**IAVI** [to 16 May 2020]

<https://www.iavi.org/newsroom>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/>

*Press Releases*

**[Norway Renews its Support for IFFIm with US\\$400 Million Pledge](#)**

08 May 2020

The 10-year commitment to support Gavi vaccine programmes is part of Norway's US\$ 1 billion commitment to Gavi London, 8 May 2020 – Norway has committed an additional US\$ 400 million over the next 10 years to the International Finance Facility for Immunisation (IFFIm), which leverages long-term donor financing.

**IFRC** [to 16 May 2020]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Selected Press Releases, Announcements*

*Global*

**International Nurses Day: Nurses deserve praise, thanks, protection amid COVID-19**

Geneva, 11 May 2020 – Nurses and other health care workers on the frontlines of the fight against COVID-19 deserve to be recognized and commended for their lifesaving efforts and personal sacrifices amid increased medical risk – and in some places amid ...

11 May 2020

**IVAC** [to 16 May 2020]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates*

**Commentary: The success of a Covid-19 vaccine will hinge on its delivery**

May 2020

By Lois Privor-Dumm, Naor Bar Zeev, and Maria Deloria Knoll Originally published on *STAT News*

The lesson learned from a long history of using vaccines to fight massively disruptive diseases like smallpox and Ebola is that the vaccine itself is not enough. Like a good punch line, it's all about the delivery. The smallpox vaccine [...]

**IVI** [to 16 May 2020]

<http://www.ivi.int/>

*Selected IVI News & Announcements*

*No new digest content identified.*

**JEE Alliance** [to 16 May 2020]

<https://www.jeealliance.org/>

*Selected News and Events*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 16 May 2020]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Sudan*

**MSF urges to respect medical action after violent incursion in Rokero, Centr...**

Statement 15 May 2020

*Coronavirus COVID-19 pandemic*

**COVID19 and lack of protective equipment threaten lifesaving care in Kenya**Project

Update 15 May 2020

*Coronavirus COVID-19 pandemic*

**COVID-19 in West Africa: "Let's prepare for a long-distance run"**

Op-Ed 15 May 2020

*Afghanistan*

**"They came to kill the mothers" in Kabul maternity hospital attack**

Voices from the Field 14 May 2020

*Afghanistan*

**Revolt on maternity ward kills pregnant women and babies...**

Press Release 13 May 2020

*Coronavirus COVID-19 pandemic*

**MSF supports the COVID-19 pandemic response in Guinea**

Project Update 12 May 2020

**National Vaccine Program Office - U.S. HHS** [to 16 May 2020]

<https://www.hhs.gov/vaccines/about/index.html>

*NVAC 2020 Meetings*

**June 9-10, 2020 NVAC Meeting**

**September 23-24, 2020 Meeting (Virtual)**

**NIH** [to 16 May 2020]

<http://www.nih.gov/news-events/news-releases>

*Selected News Releases*

**Investigational ChAdOx1 nCoV-19 vaccine protects monkeys against COVID-19 pneumonia**

May 15, 2020 — Study provided data for clinical testing to commence.

**NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19**

May 14, 2020 — Study enrolling adults with mild to moderate COVID-19 in the United States.

**Coordinated strategy to accelerate multiple COVID-19 vaccine candidates is key, NIH experts say**

May 11, 2020 — More than one effective vaccine approach likely will be required to successfully protect the global community from SARS-CoV-2.

*[See Milestones above for detail]*

**PATH** [to 16 May 2020]

<https://www.path.org/media-center/>

*Selected Announcements*  
*No new digest content identified.*

**Sabin Vaccine Institute** [to 16 May 2020]

<http://www.sabin.org/updates/pressreleases>

*Statements and Press Releases*

**[BARDA Provides the Sabin Vaccine Institute with an Additional \\$20 Million for Further Development of Ebola Sudan and Marburg Vaccines](#)**

Wednesday, May 13, 2020

*Sabin and Partner ReiThera Initiate Manufacturing of Clinical Trial Material*

WASHINGTON, D.C. and ROME, Italy, May 13, 2020 – The Sabin Vaccine Institute (Sabin) and its partner ReiThera Srl today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has exercised the first two options, valued at \$20 million, under the 2019 contract to advance the development of vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials...

**UNAIDS** [to 16 May 2020]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

16 May 2020

**[New videos highlight LGBTI issues in Brazil](#)**

14 May 2020

**[Let transgender people be in the picture](#)**

14 May 2020

**[Russian regional AIDS centres leading the fight against COVID-19](#)**

14 May 2020

**[Uniting behind a people's vaccine against COVID-19](#)**

*[See Milestones above for detail]*

13 May 2020

**[COVID-19 in prisons—a ticking time bomb](#)**

13 May 2020

**[“We are human, so of course it was scary”](#)**

13 May 2020

**[Sex workers in Bangladesh: building resilience during the COVID-19 pandemic](#)**

12 May 2020

**[People with disabilities often left behind by HIV responses](#)**

12 May 2020

## **United Nations agencies coordinate their COVID-19 response in South Africa**

11 May 2020

### **Dealing with COVID-19 in Cameroon**

11 May 2020

### **HIV testing and support for homeless people in Belarus**

**UNICEF** [to 16 May 2020]

<https://www.unicef.org/media/press-releases>

*Selected Press releases/Announcements*

*Press release*

### **Geneva Palais briefing note on UNICEF response to COVID-19 in Rohingya refugee camps as first coronavirus case confirmed**

15/05/2020

*Press release*

### **Declining vaccination rates in the Democratic Republic of the Congo could lead to resurgence in deadly diseases**

KINSHASA/GENEVA/NEW YORK, 15 May 2020 –The reduction in vaccination rates currently being reported in the Democratic Republic of the Congo (DRC) will leave children in the country at increased risk of contracting deadly diseases such as polio, measles and yellow fever, UNICEF warned today.

The decline in the first two months of the year was likely due to established challenges such as poor cold chain systems, low coverage and stock supply. However, the DRC's Expanded Programme on Immunization (EPI) is now facing a new challenge which will almost certainly worsen the situation: COVID-19. Health workers conducting routine vaccinations do not have access to adequate equipment to protect themselves, caregivers and children from the coronavirus. Parents are reluctant to attend vaccination sessions for fear of exposing themselves and their children to COVID-19...

Statement

### **Joint statement on Libya**

by OCHA, UNHCR, UNICEF, UNFPA, WFP, WHO, IOM

13/05/2020

*Press release*

### **Forced returns of migrants must be suspended in times of COVID-19**

*Statement by the United Nations Network on Migration*

GENEVA, 14 May 2020 - The United Nations Network on Migration is concerned by reports of States in many regions using forced return of migrants as a measure in response to COVID-19. The Network calls on States to suspend forced returns during the pandemic, in order to protect the health of migrants and communities, and uphold the human rights of all migrants, regardless of status. Successfully tackling the pandemic cannot be achieved without upholding human rights.

When temporary border closures and movement restrictions are deemed necessary to prevent the transmission of COVID-19, they must be implemented in a way that is non-

discriminatory and proportionate to achieving the public health aim pursued. Such closures should incorporate health protocols and processes to guarantee fundamental rights at all times.

Keeping everyone safe means ensuring that no-one faces the risk of refoulement by being returned to places where their life, safety or human rights are threatened. It means that collective expulsions, such as arbitrary pushbacks of migrants and asylum-seekers at borders, must be halted; that protection needs must be individually assessed; and that the rule of law and due process must be observed. It also means prioritizing protection, including every child's best interests. These are obligations in international law that can never be put on hold and are vital to any successful approach to combatting COVID-19 for the benefit of all...

*Press release*

**[As COVID-19 devastates already fragile health systems, over 6,000 additional children under five could die a day, without urgent action](#)**

UNICEF launches #Reimagine, a global campaign to prevent the pandemic from becoming a lasting crisis for children

12/05/2020

*Press release*

**[UNICEF appeals for \\$1.6 billion to meet growing needs of children impacted by COVID-19 pandemic](#)**

New funding request is \$1 billion more than March appeal, as countries reel from socioeconomic impact of COVID-19

11/05/2020

*Statement*

**[In light of COVID-19 crisis, UN officials call for immediate release of all children in detention, including Palestinian children](#)**

Joint Press Statement from Jamie McGoldrick, Humanitarian Coordinator in the occupied Palestinian territory (oPt), Genevieve Boutin, UNICEF Special Representative in State of Palestine, and James Heenan, Head of the UN Human Rights Office in the oPt

**Unitaid** [to 16 May 2020]

<https://unitaid.org/>

*Featured News*

14 May 2020 | Statements

**[Equitable global access to vaccines, treatments and diagnostics is key to tackling COVID-19 pandemic](#)**

Geneva – As governments, international organizations, pharmaceutical industry, academia and others focus their efforts on the COVID-19 coronavirus, it is clear that this global pandemic needs a global response. It is both a public health need and a moral duty to ensure that this response is grounded in solidarity to ensure that the vaccines, treatments and diagnostics being developed are accessible to all, everywhere and at the same time.

Heads of State and government, and the World Health Organization, have recognized and actively supported this need.

There is growing international backing for the proposal of the President of Costa Rica for voluntary pooling of knowledge, intellectual property and data necessary for COVID-19 detection, prevention, treatment and response. The pledging marathon co-hosted by the European Union and its partners on 4 May 2020 stressed the need for global development of innovative responses that are both universally available and affordable.

This political will is being translated into action through the Access to [COVID-19 Tools \(ACT\) Accelerator](#). Unitaid is proud to be part of the partnership driving the work around development, manufacturing, procurement and deployment of treatments. Core to this work must be to find innovative solutions that are adapted and accessible to all, especially in low-resource settings...

**Vaccination Acceptance Research Network (VARN)** [to 16 May 2020]

<https://vaccineacceptance.org/news.html#header1-2r>

*Announcements*

*No new digest content identified.*

**Vaccine Confidence Project** [to 16 May 2020]

<http://www.vaccineconfidence.org/>

*Latest News & Archive*

**[Building trust, managing risk around vaccines: from trials to delivery](#)**

Course Dates: 20 - 23 July 2020

This 3.5-day course, developed by the Vaccine Confidence Project<sup>TM</sup> at LSHTM, will highlight the importance of maintaining and improving vaccine confidence and explore the diversity of concerns and perceptions about vaccines and how they have impacted vaccine uptake across multiple global settings.

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 16 May 2020]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*No new digest content identified.*

**Wellcome Trust** [to 16 May 2020]

<https://wellcome.ac.uk/news>

*News | 14 May 2020*

**[Julia Gillard appointed as next Chair of Wellcome](#)**

Julia Gillard, the former Prime Minister of Australia, has been appointed as the next Chair of Wellcome. She will succeed Eliza Manningham-Buller, who is stepping down from the role in April 2021.

*News | 12 May 2020*

**[Wellcome Leap announces leadership team](#)**

Wellcome Leap, a not-for-profit organisation founded by Wellcome to accelerate innovations that benefit global health, will be led by Regina E. Dugan as CEO and Jay Flatley as Chair.



With initial funding of \$300 million, [Wellcome Leap](#) will undertake bold, unconventional programmes and fund them at scale. These programmes will target complex human health challenges with the goal of achieving breakthrough scientific and technological solutions within a decade...

**The Wistar Institute** [to 16 May 2020]  
<https://www.wistar.org/news/press-releases>  
*Press Releases*  
*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 16 May 2020]  
<https://www.wfpha.org/>  
*Latest News*  
*No new digest content identified.*

**World Organisation for Animal Health (OIE)** [to 16 May 2020]  
<https://www.oie.int/en/for-the-media/press-releases/2020/>  
*Press Releases*  
*No new digest content identified.*

.....

**ARM [Alliance for Regenerative Medicine]** [to 16 May 2020]  
<https://alliancerm.org/press-releases/>  
*Press Releases*  
*No new digest content identified.*

**BIO** [to 16 May 2020]  
<https://www.bio.org/press-releases>  
*Press Releases*  
**Modernized Biotech Regulation Will Unleash Greater Innovation**

May 14, 2020

The U.S. Department of Agriculture (USDA) released today a modernized, science-based regulatory system for plant biotechnology aimed at maintaining oversight while driving innovation. Now government and industry must do more to build an informed and...

**BIO Appoints a Physician-Scientist as New President and CEO**

May 14, 2020

Immunologist Michelle McMurry-Heath is Selected for Her Global Leadership and Commitment to Innovation and Patients Former FDA Official Will Succeed Industry Leader Jim Greenwood on June 1 as Leader of World's Largest Biotechnology...

**Dr. Moncef Slaoui "Excellent Choice" to Lead Operation Warp Speed**

May 13, 2020

Following the announcement that Dr. Moncef Slaoui will lead the Trump Administration's "Operation Warp Speed" initiative, BIO's President and CEO, Jim Greenwood, issued the following statement: "Dr. Moncef Slaoui is an excellent choice..."

### **New Medicine Pipeline Tracker Illustrates Unprecedented Effort to Eradicate COVID-19**

May 12, 2020

The Biotechnology Innovation Organization (BIO) today unveiled a first-of-its-kind, interactive tracker of the new treatments and vaccines in the COVID-19 pipeline. This online resource illustrates the unprecedented campaign being undertaken by...

### **DCVMN – Developing Country Vaccine Manufacturers Network** [to 16 May 2020]

<http://www.dcvmn.org/>

*News*

9 May 2020

### **DCVMN united with the EU at the Coronavirus Global Response international pledging event**

Brussels, 04 May 2020 - Governments, global health organizations, and experienced partners joined hands...

### **IFPMA** [to 16 May 2020]

<http://www.ifpma.org/resources/news-releases/>

*Selected Press Releases, Statements, Publications*

### **COVID-19 Biopharmaceutical Industry – Regulatory Guiding Principles**

Published on: 14 May 2020

During these unprecedented times, it is essential that we all come together to contribute to the development of medicines and vaccines for treatment and prevention of COVID-19.

Many activities, undertaken by governments, national regulatory authorities (NRAs), academia, global health stakeholders and the biopharmaceutical industry, are helping to identify, research, develop and manufacture at scale these vital technologies under immense time pressure.

While resources are being committed to address the pandemic, other equally important efforts must continue for the benefit of patients globally beyond COVID-19. Access to existing medicines and vaccines for treatment and prevention of other conditions, like diabetes, cancer and measles, must continue. Clinical research into new options and treatments for serious and life-threatening diseases and unmet medical needs should be preserved.

Despite the huge impact caused by COVID-19, the R&D-based biopharmaceutical industry must maintain and indeed increase the supply of medicines and vaccines to the best of our ability to patients at a time when 'normal' production, supply chains and business operations are adversely impacted and massively challenged.

With a need for increased speed and a 'new' normal comes unprecedented pressure on biopharmaceutical manufacturing, which we are committed to meeting whilst not affecting patient safety and quality.

Therefore, we would like to reiterate our continued commitments to:

**:: Working in partnership and collaboration with NRAs to define the best science-based regulatory strategies for ensuring the availability of COVID-19 medicines and vaccines** – Implementing new principles (e.g. regulatory reliance and mutual recognition) and enhancing existing approaches for clinical research, pharmaceutical production and advancement of new COVID-19 medicines and vaccines are critical for global public health.

**:: Progressing research into new treatments and prevention of other conditions** – We are committed to adhering to the best principles for conducting clinical research and ensuring the continuation of ongoing clinical trials for promising, non-COVID-19 treatments.

**:: Maintaining supply of medicines and vaccines** – Enabling continuity of manufacturing and availability of product supply is imperative for public health. Globally integrated supply chains, which ensure quality, safety and innovative approaches for distribution across the health sector, may be critically impacted by operational disruptions. We work to find solutions that address potential bottlenecks and barriers thereby avoiding disruptions that could jeopardize access to treatments.

**:: Ensuring all our medicines and vaccines continue to meet appropriate standards for quality and safety** – Patient safety and product quality are key priorities for the biopharmaceutical industry and are intrinsic to what we do. We routinely engage with regulatory and standard-setting bodies in the development and implementation of guidelines for the quality and safety of medicines and vaccines. We also monitor the use of our medicines and vaccines with patients to safeguard and promote public health.

**PhRMA** [to 16 May 2020]

<http://www.phrma.org/>

*Selected Press Releases, Statements*

*No new digest content identified.*

**Industry Watch** [to 16 May 2020]

**:: Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age**

*20-valent pneumococcal conjugate vaccine elicits consistent immune response across three different lots*

May 14, 2020 NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced top-line results from a second Phase 3 study (NCT03828617), which described the safety and evaluated the consistency of immune responses elicited across three different lots of its 20-valent pneumococcal polysaccharide conjugate vaccine (20vPnC) candidate in adults 18 through 49 years of age not previously vaccinated against pneumococcal disease. Responses elicited by 20vPnC for all 20 serotypes were equivalent across all three lots, meeting the primary immunogenicity objective of the study. In this study the 20vPnC safety profile was similar to the Prevnar 13® (pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) control group. This clinical lot consistency study is expected to satisfy licensure requirements for

manufacturing consistency by the U.S. Food and Drug Administration, and other countries' regulatory agencies.

"We are excited by the progress of our adult development program for 20vPnC as this is the second phase 3 trial for this investigational vaccine for which we have positive topline data," said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer...

\* \* \* \*

### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **American Journal of Infection Control**

May 2020 Volume 48, Issue 5, p471-590

<http://www.ajicjournal.org/current>

#### ***The Importance of Hand Hygiene in the Current Healthcare Environment***

[Reviewed earlier]

### **American Journal of Preventive Medicine**

May 2020 Volume 58, Issue 5, p613-756

<http://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

May 2020 110(5)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 102, Issue 4, April 2020

<http://www.ajtmh.org/content/journals/14761645/102/4>

[Reviewed earlier]

### **Annals of Internal Medicine**

5 May 2020 Volume 172, Issue 9

<http://annals.org/aim/issue>

*Original Research*

**The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application**

FREE

Stephen A. Lauer, MS, PhD, Kyra H. Grantz, BA, Qifang Bi, MHS, Forrest K. Jones, MPH, Qulu Zheng, MHS, ... et al.

Using news reports and press releases from provinces, regions, and countries outside Wuhan, Hubei province, China, this analysis estimates the length of the incubation period of COVID-19 and its public health implications.

*Ideas and Opinions*

**Coronavirus Disease 2019 (COVID-19): Protecting Hospitals From the Invisible**

FREE

Michael Klompas, MD, MPH

COVID-19 is optimized to spread widely: Its signs and symptoms are largely indistinguishable from those of other respiratory viruses. This commentary specifically addresses best ways to protect our hospitals against COVID-19.

**How Should U.S. Hospitals Prepare for Coronavirus Disease 2019 (COVID-19)?**

FREE

Vineet Chopra, MD, MSc, Eric Toner, MD, Richard Waldhorn, MD, and Laraine Washer, MD

Estimates suggest that COVID-19 will stress bed capacity, equipment, and health care personnel in U.S. hospitals in ways not previously experienced. How can health systems prepare to care for a large influx of patients with this disease?

**Artificial Intelligence – An International Journal**

Volume 282 May 2020

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/282/suppl/C>

[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 16 May 2020)

[No new digest content identified]

**BMJ Global Health**

April 2020 - Volume 5 - Suppl 1

[https://gh.bmj.com/content/5/Suppl\\_1](https://gh.bmj.com/content/5/Suppl_1)

***Reaching conflict-affected women and children with health and nutrition interventions***

[Reviewed earlier]

## **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 16 May 2020)

### **[Uptake and acceptability of human papillomavirus self-sampling in rural and remote aboriginal communities: evaluation of a nurse-led community engagement model](#)**

*Aboriginal women experience disproportionately higher rates of cervical cancer mortality yet are less likely to participate in screening for early detection. This study sought to determine whether a community...*

Authors: Tegan Dutton, Jo Marjoram, Shellie Burgess, Laurinne Montgomery, Anne Vail, Nichole Callan, Sunil Jacob, David Hawkes, Marion Saville and Jannine Bailey

Citation: BMC Health Services Research 2020 20:398

Content type: Research article

Published on: 11 May 2020

## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 16 May 2020)

[No new digest content identified]

## **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 16 May 2020)

### **[Prioritising access to pandemic influenza vaccine: a review of the ethics literature](#)**

Authors: Jane H. Williams and Angus Dawson

Citation: BMC Medical Ethics 2020 21:40

Content type: Review

Published on: 14 May 2020

#### *Abstract*

#### Background

The world is threatened by future pandemics. Vaccines can play a key role in preventing harm, but there will inevitably be shortages because there is no possibility of advance stockpiling. We therefore need some method of prioritising access.

#### Main text

This paper reports a critical interpretative review of the published literature that discusses ethical arguments used to justify how we could prioritise vaccine during an influenza pandemic. We found that the focus of the literature was often on proposing different groups as priorities (e.g. those with pre-existing health conditions, the young, the old, health care workers etc.). Different reasons were often suggested as a means of justifying such priority groupings (e.g. appeal to best overall outcomes, fairness, belonging to a vulnerable or 'at risk' group etc.). We suggest that much of the literature, wrongly, assumes that we are able to plan priority groups prior to the time of a particular pandemic and development of a particular vaccine. We also point out the surprising absence of various issues from the literature (e.g. how vaccines fit within overall pandemic planning, a lack of specificity about place, issues of global justice etc.).

#### Conclusions

The literature proposes a wide range of ways to prioritise vaccines, focusing on different groups and 'principles'. Any plan to use pandemic vaccine must provide justifications for its

prioritisation. The focus of this review was influenza pandemic vaccines, but lessons can be learnt for future allocations of coronavirus vaccine, if one becomes available.

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmmed/content>

(Accessed 16 May 2020)

[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 16 May 2020)

[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 16 May 2020)

#### **[Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland](#)**

*An infection with high-risk human papillomavirus (HPV) is the obligatory aetiological factor for the development of cervical cancer. In Switzerland, the prevention strategy for cervical cancer is based on prim...*

Authors: André B. Kind, Andrew Pavelyev, Smita Kothari, Nadia El Mouaddin, Aurélie Schmidt, Edith Morais, Patrik Guggisberg and Florian Lienert

Citation: BMC Public Health 2020 20:671

Content type: Research article

Published on: 12 May 2020

#### **[Vaccination card availability and childhood immunization in Senegal](#)**

*The World Health Organization recommends recording vaccination status according to maternal recall in countries where administrative reporting systems are insufficiently reliable, as maternal recall in develop...*

Authors: Valérie Seror, Sébastien Cortaredona, Elhadji Yaya Ly, Samba Ndiaye, Ibrahima Gaye, Mouhamadou Fall and Patrick Peretti-Watel

Citation: BMC Public Health 2020 20:658

Content type: Research article

Published on: 12 May 2020

#### **[Interventions to increase uptake of cervical screening in sub-Saharan Africa: a scoping review using the integrated behavioral model](#)**

*Sub-Saharan Africa (SSA) experiences disproportionate burden of cervical cancer incidence and mortality due in part to low uptake of cervical screening, a strategy for prevention and down-staging of cervical c...*

Authors: Breanne E. Lott, Mario J. Trejo, Christina Baum, D. Jean McClelland, Prajakta Adsul, Purnima Madhivanan, Scott Carvajal, Kacey Ernst and John Ehiri

Citation: BMC Public Health 2020 20:654  
Content type: Research article  
Published on: 11 May 2020

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>  
(Accessed 16 May 2020)  
[No new digest content identified]

### **BMJ Open**

May 2020 - Volume 10 - 5  
<https://bmjopen.bmj.com/content/10/5>  
[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 98, Number 5, May 2020  
<https://www.who.int/bulletin/volumes/98/5/en/>  
[Reviewed earlier]

### **Child Care, Health and Development**

Volume 46, Issue 3 Pages: 249-396 May 2020  
<https://onlinelibrary.wiley.com/toc/13652214/current>  
[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 107, Issue 6 Pages: 1263-1457 June 2020  
<https://ascpt.onlinelibrary.wiley.com/toc/15326535/2020/107/6>  
*Perspectives*

#### **Grounding Value-Based Drug Pricing in Population Health**

Anna Kaltenboeck, Maura Calsyn, Geert W.J. Frederix, Justin Lowenthal, David Mitchell, Bruce Rector, Ameet Sarpatwari  
Pages: 1290-1292  
First Published: 17 January 2020

### **Clinical Therapeutics**

April 2020 Volume 42, Issue 4, p551-728, e65-e86  
<http://www.clinicaltherapeutics.com/current>  
[Reviewed earlier]

### **Clinical Trials**

Volume 17 Issue 2, April 2020



<https://journals.sagepub.com/toc/ctja/17/1>  
[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>  
[Accessed 16 May 2020]  
[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 90 March 2020  
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/90/suppl/C>  
[Reviewed earlier]

### **The CRISPR Journal**

Volume 3, Issue 2 / April 2020  
<https://www.liebertpub.com/toc/crispr/3/2>  
[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 8, Issue 1, March 2020  
<https://link.springer.com/journal/40142/8/1>  
[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

June 2020 - Volume 33 - Issue 3  
<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>  
[Reviewed earlier]

### **Developing World Bioethics**

Volume 20, Issue 1 Pages: 1-60 March 2020  
<https://onlinelibrary.wiley.com/toc/14718847/current>  
[Reviewed earlier]

### **Development in Practice**

Volume 30, Issue 2, 2020  
<http://www.tandfonline.com/toc/cdip20/current>  
[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 14 - Issue 1 - February 2020

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 44, Issue 2 Pages: 233-432 April 2020

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

### **EMBO Reports**

Volume 21 Issue 5 6 May 2020

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 26, Number 5—May 2020

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

### **Epidemics**

Volume 30 March 2020

<https://www.sciencedirect.com/journal/epidemics/vol/30/suppl/C>

[Reviewed earlier]

### **Epidemiology and Infection**

Volume 148 - 2020

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 42, Issue 2 Pages: 1-33 March–April 2020

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Incidental Findings :: Data Sharing N-of-1 Trials :: Deception***

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 30, Issue 2, April 2020

<https://academic.oup.com/eurpub/issue/30/2>

[Reviewed earlier]

## **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 16 May 2020]

[No new digest content identified]

## **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 16 May 2020]

[No new digest content identified]

## **Global Health Action**

Volume 12, 2019 Issue 1

<https://www.tandfonline.com/toc/zgha20/12/sup1?nav=tocList>

[Reviewed earlier]

## **Global Health: Science and Practice (GHSP)**

Vol. 8, No. 1 March 30, 2020

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

## **Global Public Health**

Volume 15, 2020 Issue 6

<http://www.tandfonline.com/toc/rgph20/current>

*Article*

### **[Access to innovative medicines by pharma companies: Sustainable initiatives for global health or useful advertisement?](#)**

Michele de Medeiros Rocha, Emmanuel Paiva de Andrade, Edna Ribeiro Alves, João Carlos Cândido & Marcello de Miranda Borio

Pages: 777-789

Published online: 18 Feb 2020

#### ***ABSTRACT***

Research & Development on new medicines plays an important role in life and well-being, making pharmaceutical companies important players in global health. Accessibility and financing new medicines, however, poses challenges for governments and patients around the world. Due to pricing and aggressive patent policy issues, pharma companies started to adopt access to medicines as a strategy to not only improve their public image but also to increase their economic performance. More than a useful institutional advertisement to attract new business, initiatives to improve access to medicines must be socially responsible and sustainable. Using content analysis methodology from CSR reports, the present study evaluated how 44 global companies are positioning themselves regarding access, whether these initiatives are aligned to existing access programmes and whether the actions disclosed on behalf of access are sustainable. We have identified 13 major access to medicines approaches that were classified into intrinsic, potentially sustainable and robust actions. We concluded that companies overvalue the term access to medicine. This can generate initiatives focused on advertisements

rather than long-term actions and highlights the need for clear global criteria for companies and programmes that want to effectively publicise access to medicines as a social responsibility strategy.

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 16 May 2020]

#### **COVID-19 in Africa: care and protection for frontline healthcare workers**

Authors: Matthew F. Chersich, Glenda Gray, Lee Fairlie, Quentin Eichbaum, Susannah Mayhew, Brian Allwood, Rene English, Fiona Scorgie, Stanley Luchters, Greg Simpson, Marjan Mosalman Haghighi, Minh Duc Pham and Helen Rees

Content type: Review

15 May 2020

#### **Impact of international travel dynamics on domestic spread of 2019-nCoV in India: origin-based risk assessment in importation of infected travelers**

Authors: Sachin S. Gunthe and Satya S. Patra

Content type: Commentary

12 May 2020

### **Health Affairs**

Vol. 39, No. 4 April 2020

<https://www.healthaffairs.org/toc/hlthaff/current>

#### ***Integrating Social Services & Health***

[Reviewed earlier]

### **Health and Human Rights**

<https://www.hhrjournal.org>

[Accessed 16 May 2020]

[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 15 - Issue 2 - April 2020

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

### **Health Policy and Planning**

Volume 35, Issue 4, May 2020,

<https://academic.oup.com/heapol/issue/35/4>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 16 May 2020]

**[Exploring why global health needs are unmet by research efforts: the potential influences of geography, industry and publication incentives](#)**

Authors: Alfredo Yegros-Yegros, Wouter van de Klippe, Maria Francisca Abad-Garcia and Ismael Rafols

Content type: Research

15 May 2020

**Human Gene Therapy**

Volume 31, Issue 9-10 / May 2020

<https://www.liebertpub.com/toc/hum/31/9-10>

[New issue; No digest content identified]

**Humanitarian Exchange Magazine**

Number 77, March 2020

<https://odihpn.org/magazine/the-crisis-in-yemen/>

***Responding to Ebola in the Democratic Republic of Congo***

by Humanitarian Practice Network

This edition of Humanitarian Exchange, co-edited with Anne Harmer, focuses on the response to the Ebola outbreak in the Democratic Republic of Congo (DRC). Although at the time of publication the outbreak appeared to have ended, over its course it claimed 2,200 lives, with more than 3,300 infected, making this the world's second largest outbreak ever.

In the lead article, Natalie Roberts reflects on the extent to which humanitarian actors have applied learning from the outbreak in West Africa in 2014–2016. Richard Kojan and colleagues report on the NGO ALIMA's flexible, patient-centred approach to reducing mortality, Marcela Ascuntar reflects on lessons learned from community feedback and Bernard Balibuno, Emanuel Mbuna Badjonga and Howard Mollett highlight the crucial role faith-based organisations have played in the response. In their article, Theresa Jones, Noé Kasali and Olivia Tulloch outline the work of the Bethesda counselling centre in Beni, which provides support to grieving families. Reflecting on findings from a recent assessment by Translators without Borders, Ellie Kemp describes the challenges involved in providing clear and accessible information on Ebola and the response, and Sung Joon Park and colleagues explain how humane care and treatment can help increase trust and confidence in the response. Stephen Mugamba and his co-authors highlight the importance of community involvement in Ebola research, and Gillian McKay and her co-authors examine the impact of the Ebola outbreak and response on sexual and reproductive health services.

Stacey Mearns, Kiryn Lanning and Michelle Gayer present an Ebola Readiness Roadmap to support NGOs in preparing for an outbreak, while Edward Kumakech, Maurice Sadlier, Aidan Sinnott and Dan Irvine report on a Gap Analysis tool looking at the communication, community engagement and compliance tracking activities that need to be in place before an Ebola vaccine is deployed. Emanuele Bruni and colleagues describe the development of a new monitoring and evaluation framework for strategic response planning. The edition ends with an article by

Adelicia Fairbanks, who argues for an acceptance strategy in the DRC to improve security and access for responding agencies.

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 16, Issue 4, 2020

<http://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

**Infectious Agents and Cancer**

<http://www.infectagentscancer.com/content>

[Accessed 16 May 2020]

[No new digest content identified]

**Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 16 May 2020]

[No new digest content identified]

**International Health**

Volume 12, Issue 3, May 2020,

<https://academic.oup.com/inthealth/issue/12/3>

[Reviewed earlier]

**International Journal of Community Medicine and Public Health**

Vol 7, No 5 (2020) May 2020

<https://www.ijcmph.com/index.php/ijcmph/issue/view/62>

[Reviewed earlier]

**International Journal of Epidemiology**

Volume 49, Issue Supplement\_1, April 2020

[https://academic.oup.com/ije/issue/49/Supplement\\_1](https://academic.oup.com/ije/issue/49/Supplement_1)

***Big Data, Small Area***

[Reviewed earlier]

**International Journal of Human Rights in Healthcare**

Volume 13 Issue 1 2020

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/13/iss/1>

[New issue; No digest content identified]

**International Journal of Infectious Diseases**

April 2020 Volume 93, p1-388

[https://www.ijidonline.com/issue/S1201-9712\(20\)X0003-8](https://www.ijidonline.com/issue/S1201-9712(20)X0003-8)

*Editorials*

**Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the future**

Nathan Kapata, Chikwe Ihekweazu, Francine Ntoumi, Tajudeen Raji, Pascalina Chanda-Kapata, Peter Mwaba, Victor Mukonka, Matthew Bates, John Tembo, Victor Corman, Sayoki Mfinanga, Danny Asogun, Linzy Elton, Liã Bárbara Arruda, Margaret J. Thomason, Leonard Mboera, Alexei Yavlinsky, Najmul Haider, David Simons, Lara Hollmann, Swaib A. Lule, Francisco Veas, Muzamil Mahdi Abdel Hamid, Osman Dar, Sarah Edwards, Francesco Vairo, Timothy D. McHugh, Christian Drosten, Richard Kock, Giuseppe Ippolito, Alimuddin Zumla  
p233–236

Published online: February 28, 2020

*Original Reports*

**Who and when to vaccinate against influenza**

Philippe Buchy, Selim Badur

p375–387

Published online: February 25, 2020

**Immune response to different types of hepatitis B vaccine booster doses 2–32 years after the primary immunization schedule and its influencing factors**

Yu-Liang Zhao, Lu-Lu Pan, Zhi-Yong Hao, Fei Jin, Yan-Hong Zhang, Min-Jie Li, Xin-Jiang Zhang, Bi-Hua Han, Hai-Song Zhou, Tian-Li Ma, Feng Wang, Jing-Chen Ma, Li-Peng Shen, Qi Li  
p62–67

Published online: January 28, 2020

**Evaluation of the effectiveness of pneumococcal conjugate vaccine for children in Korea with high vaccine coverage using a propensity score matched national population cohort**

Sangho Sohn, Kwan Hong, Byung Chul Chun

p146–150

Published online: January 23, 2020

**JAMA**

May 12, 2020, Vol 323, No. 18, Pages 1749-1862

<https://jamanetwork.com/journals/jama/currentissue>

*Research Letter*

**Ethics Committee Reviews of Applications for Research Studies at 1 Hospital in China During the 2019 Novel Coronavirus Epidemic**

Hui Zhang, MBBS; Fengmin Shao, MD, PhD; Jianqin Gu, MD, PhD; et al.

free access has active quiz

JAMA. 2020;323(18):1844-1846. doi:10.1001/jama.2020.4362

This study reviews research ethics committee applications for COVID-19–related research at a Chinese hospital in February 2020 to characterize study type, approval rate and review time, reason for revision or denial, and issues with informed consent.

### *...Results*

Ethics review conferences, held once every month in nonepidemic periods, were held 4 times in 35 days. The mean time was 2.13 days from application submissions until an initial review decision was made. For applications that required modifications, the mean time was 1.81 days for the resubmission to be reviewed again.

Forty-one applications were reviewed, including interventional studies (n = 21); diagnostic studies (n = 7); observational studies (n = 10); and other types (n = 3). Six (14.6%) were approved; 4 (9.8%), rejected; and 31 (75.6%), referred for modification.

Of the 4 rejected applications, 2 were denied because 1 involved a new, unapproved interferon-alfa treatment and another involved traditional Chinese medicine with many potential adverse reactions, so the potential risks outweighed benefits. The other 2 studies were denied because the laboratory biosafety level was inadequate, which may have led to virus leakage.

Of the 31 applications that required modifications, the issues with the research proposals and informed consent forms are indicated in [Table 1](#) and [Table 2](#). The most frequent issues with proposals were lack of statistical basis for the sample size calculation and deficiencies in inclusion and exclusion criteria. The most frequent issues with informed consent forms were that patients were not informed of the risks and that compensation was unreasonable.

### *Viewpoint*

#### **The COVID-19 Pandemic in the USA Clinical Update**

Saad B. Omer, MBBS, PhD; Preeti Malani, MD, MSJ; Carlos del Rio, MD  
free access has active quiz has multimedia has audio  
JAMA. 2020;323(18):1767-1768. doi:10.1001/jama.2020.5788

This Viewpoint provides a summary update of coronavirus disease 2019 (COVID-19) in the US, discussing case-fatality rates, interpretation of polymerase chain reaction test results, duration of immunity, reinfection, and more.

[Audio Interview:](#) Coronavirus (COVID-19) Update: Clinical Review

### *Editorial*

#### **A Bold Response to the COVID-19 Pandemic Medical Students, National Service, and Public Health**

Howard Bauchner, MD; Joshua Sharfstein, MD

#### **A Framework for Rationing Ventilators and Critical Care Beds During the COVID-19 Pandemic**

Douglas B. White, MD, MAS; Bernard Lo, MD  
free access has active quiz has multimedia has audio  
JAMA. 2020;323(18):1773-1774. doi:10.1001/jama.2020.5046

This Viewpoint describes a framework for rationing ventilators during the COVID-19 pandemic should intensive care units find themselves with more patients than they can care for, using a score-based system that incorporates patients' likelihood of surviving to hospital discharge and beyond and their role in the public health response to the outbreak.

[Audio Interview:](#) Coronavirus (COVID-19) Update: Fairly Rationing ICU Care

### *Review*

#### **Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review**

James M. Sanders, PhD, PharmD; Marguerite L. Monogue, PharmD; Tomasz Z. Jodlowski, PharmD; et al.



free access has active quiz

JAMA. 2020;323(18):1824-1836. doi:10.1001/jama.2020.6019

This narrative review summarizes what is currently known about how SARS-CoV-2 infects cells and causes disease as a basis for considering whether chloroquine, remdisivir and other antivirals, or other existing drugs might be effective treatment for coronavirus disease 2019 (COVID-19).

### **JAMA Pediatrics**

May 2020, Vol 174, No. 5, Pages 401-512

<http://archpedi.jamanetwork.com/issue.aspx>

[Reviewed earlier]

### **JB I Database of Systematic Review and Implementation Reports**

April 2020 - Volume 18 - Issue 4

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Adolescent Health**

May 2020 Volume 66, Issue 5, p515-634

[https://www.jahonline.org/issue/S1054-139X\(20\)X0005-X](https://www.jahonline.org/issue/S1054-139X(20)X0005-X)

[Reviewed earlier]

### **Journal of Artificial Intelligence Research**

Vol. 68 (2020)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

### **Journal of Community Health**

Volume 45, Issue 3, June 2020

<https://link.springer.com/journal/10900/45/3>

[Reviewed earlier]

### **Journal of Development Economics**

Volume 144 May 2020

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/144/suppl/C>

[Reviewed earlier]

### **Journal of Empirical Research on Human Research Ethics**

Volume 15 Issue 1-2, February-April 2020

<http://journals.sagepub.com/toc/jre/current>

***Special Issue: Ethical Issues in Social Media Research***

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

April 2020 - Volume 74 - 4

<https://jech.bmj.com/content/74/4>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 13, Issue 1 Pages: 1-88 February 2020

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 16, Issue 1, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[New issue; No digest content identified]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 31, Number 1, February 2020

<https://muse.jhu.edu/journal/278>

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 22, Issue 3, June 2020

<https://link.springer.com/journal/10903/22/3>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 18, 2020\_ Issue 2

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 221, Issue 7, 1 April 2020

<https://academic.oup.com/jid/issue/221/7>

[Reviewed earlier]

**Journal of Medical Ethics**

May 2020 - Volume 46 - 5

<http://jme.bmj.com/content/current>

*The concise argument*

**[Ethics in a time of coronavirus](#)** (14 May, 2020) Free  
Kenneth Boyd

**Journal of Patient-Centered Research and Reviews**

Volume 7, Issue 2 (2020)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

[Reviewed earlier]

**Journal of Pediatrics**

May 2020 Volume 220, p1-274

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 16 May 2020]

**[Current regulatory approaches for accessing potential COVID-19 therapies](#)**

Authors: Vesa Halimi, Armond Daci, Simona Stojanovska, Irina Panovska-Stavridis, Milena Stevanovic, Venko Filipce and Aleksandra Grozdanova

Content type: Commentary

16 May 2020

*Abstract*

This commentary aims to elaborate challenges in the regulatory approaches for accessing and investigating COVID-19 potential therapies either with off-label use, compassionate use, emergency use or for clinical trials. Since no therapies have been formally approved and completely effective and safe to date, the best clinical choice is acquired only after consistent and fair communication and collaboration between licensed clinicians, researchers, regulatory authorities, manufacturers and patients.

**Journal of Public Health Management & Practice**

May/June 2020 - Volume 26 - Issue 3

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 41, Issue 2, June 2020

<https://link.springer.com/journal/41271/41/2>

*Original Article*

**[Toward universal human papillomavirus vaccination for adolescent girls in Hong Kong: a policy analysis](#)**

Ruirui Chen, Eliza Wong, Lijuan Wu, Yuanfang Zhu

### **Journal of Refugee & Global Health**

Volume 2, Issue 2 (2019)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

### **Journal of the Royal Society – Interface**

May 2020 Volume 17 Issue 166

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

### **Journal of Travel Medicine**

Volume 27, Issue 2, March 2020

<https://academic.oup.com/jtm/issue/27/2>

[Reviewed earlier]

### **Journal of Virology**

April 2020; Volume 94, Issue 8

<http://jvi.asm.org/content/current>

[Reviewed earlier]

### **The Lancet**

May 16, 2020 Volume 395 Number 10236 p1521-1586, e83-e89

<https://www.thelancet.com/journals/lancet/issue/current>

*Editorial*

#### **Reviving the US CDC**

The Lancet

The COVID-19 pandemic continues to worsen in the USA with 1·3 million cases and an estimated death toll of 80 684 as of May 12. States that were initially the hardest hit, such as New York and New Jersey, have decelerated the rate of infections and deaths after the implementation of 2 months of lockdown. However, the emergence of new outbreaks in Minnesota, where the stay-at-home order is set to lift in mid-May, and Iowa, which did not enact any restrictions on movement or commerce, has prompted pointed new questions about the inconsistent and incoherent national response to the COVID-19 crisis.

The US Centers for Disease Control and Prevention (CDC), the flagship agency for the nation's public health, has seen its role minimised and become an ineffective and nominal adviser in the response to contain the spread of the virus. The strained relationship between the CDC and the federal government was further laid bare when, according to The Washington Post, Deborah Birx, the head of the US COVID-19 Task Force and a former director of the CDC's Global HIV/AIDS Division, cast doubt on the CDC's COVID-19 mortality and case data by reportedly saying: "[There is nothing from the CDC that I can trust](#)". This is an unhelpful statement, but also a shocking indictment of an agency that was once regarded as the gold standard for global disease detection and control. How did an agency that was the first point of contact for many

national health authorities facing a public health threat become so ill-prepared to protect the public's health?

In the decades following its founding in 1946, the CDC became a national pillar of public health and globally respected. It trained cadres of applied epidemiologists to be deployed in the USA and abroad. CDC scientists have helped to discover new viruses and develop accurate tests for them. CDC support was instrumental in helping WHO to eradicate smallpox. However, funding to the CDC for a long time has been subject to conservative politics that have increasingly eroded the agency's ability to mount effective, evidence-based public health responses. In the 1980s, the Reagan administration resisted providing the sufficient budget that the CDC needed to fight the HIV/AIDS crisis. The George W Bush administration put restrictions on global and domestic HIV prevention and reproductive health programming.

The Trump administration further chipped away at the CDC's capacity to combat infectious diseases. CDC staff in China were cut back with the last remaining CDC officer recalled home from the [China CDC in July, 2019](#), leaving an intelligence vacuum when COVID-19 began to emerge. In a press conference on Feb 25, Nancy Messonnier, director of the CDC's National Center for Immunization and Respiratory Diseases, warned US citizens to prepare for major disruptions to movement and everyday life. Messonnier subsequently no longer appeared at White House briefings on COVID-19. More recently, the Trump administration has questioned guidelines that the CDC has provided. These actions have undermined the CDC's leadership and its work during the COVID-19 pandemic.

There is no doubt that the CDC has made mistakes, especially on testing in the early stages of the pandemic. The agency was so convinced that it had contained the virus that it retained control of all diagnostic testing for severe acute respiratory syndrome coronavirus 2, but this was followed by the admission on Feb 12 that the CDC had developed [faulty test kits](#). The USA is still nowhere near able to provide the basic surveillance or laboratory testing infrastructure needed to combat the COVID-19 pandemic.

But punishing the agency by marginalising and hobbling it is not the solution. The Administration is obsessed with magic bullets—vaccines, new medicines, or a hope that the virus will simply disappear. But only a steadfast reliance on basic public health principles, like test, trace, and isolate, will see the emergency brought to an end, and this requires an effective national public health agency. The CDC needs a director who can provide leadership without the threat of being silenced and who has the technical capacity to lead today's complicated effort.

The Trump administration's further erosion of the CDC will harm global cooperation in science and public health, as it is trying to do by defunding WHO. A strong CDC is needed to respond to public health threats, both domestic and international, and to help prevent the next inevitable pandemic. Americans must put a president in the White House come January, 2021, who will understand that public health should not be guided by partisan politics.

*Comment*

### **What policy makers need to know about COVID-19 protective immunity**

Daniel M Altmann, Daniel C Douek, Rosemary J Boyton

... Most of the available COVID-19 serology data derive from people who have been hospitalised with severe infection.[8,18](#) In this group, around 90% develop IgG antibodies within

the first 2 weeks of symptomatic infection and this appearance coincides with disappearance of virus,<sup>18</sup> supporting a causal relationship between these events. However, a key question concerns antibodies in non-hospitalised individuals who either have milder disease or no symptoms. Anecdotal results from community samples yield estimates of under 10% of tested “controls” developing specific IgG antibodies. We await larger seroprevalence datasets, but it seems likely that natural exposure during this pandemic might, in the short to medium term, not deliver the required level of herd immunity and there will be a substantial need for mass vaccination programmes...

### **The COVID-19 response for vulnerable people in places affected by conflict and humanitarian crises**

David Nott

#### *Articles*

#### **Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial**

Yeming Wang, et al.

#### *Review*

#### **Artificial intelligence and the future of global health**

Nina Schwalbe, Brian Wahl

#### *Summary*

Concurrent advances in information technology infrastructure and mobile computing power in many low and middle-income countries (LMICs) have raised hopes that artificial intelligence (AI) might help to address challenges unique to the field of global health and accelerate achievement of the health-related sustainable development goals. A series of fundamental questions have been raised about AI-driven health interventions, and whether the tools, methods, and protections traditionally used to make ethical and evidence-based decisions about new technologies can be applied to AI. Deployment of AI has already begun for a broad range of health issues common to LMICs, with interventions focused primarily on communicable diseases, including tuberculosis and malaria. Types of AI vary, but most use some form of machine learning or signal processing. Several types of machine learning methods are frequently used together, as is machine learning with other approaches, most often signal processing. AI-driven health interventions fit into four categories relevant to global health researchers: (1) diagnosis, (2) patient morbidity or mortality risk assessment, (3) disease outbreak prediction and surveillance, and (4) health policy and planning. However, much of the AI-driven intervention research in global health does not describe ethical, regulatory, or practical considerations required for widespread use or deployment at scale. Despite the field remaining nascent, AI-driven health interventions could lead to improved health outcomes in LMICs. Although some challenges of developing and deploying these interventions might not be unique to these settings, the global health community will need to work quickly to establish guidelines for development, testing, and use, and develop a user-driven research agenda to facilitate equitable and ethical use.

### **The Lancet Child & Adolescent Health**

May 2020 Volume 4 Number 5 p341-406, e10-e11

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

### **Lancet Digital Health**

May 2020 Volume 2 Number 5 e209-e267

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

### **Lancet Global Health**

May 2020 Volume 8 Number 5 e612-e736

<http://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

### **Lancet Infectious Diseases**

May 2020 Volume 20 Number 5 p511-628, e79-e115

<http://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

### **Lancet Public Health**

May 2020 Volume 5 Number 5 e235-e296

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

### **Lancet Respiratory Medicine**

May 2020 Volume 8 Number 5 p423-526, e27-e42

<http://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

### **Maternal and Child Health Journal**

Volume 24, Issue 5, May 2020

<https://link.springer.com/journal/10995/24/5>

[New issue; No digest content identified]

### **Medical Decision Making (MDM)**

Volume 40 Issue 2, February 2020

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 98, Issue 1 Pages: 1-222 March 2020

<https://onlinelibrary.wiley.com/toc/14680009/current>  
[Reviewed earlier]

## **Nature**

Volume 581 Issue 7807, 14 May 2020

[http://www.nature.com/nature/current\\_issue.html](http://www.nature.com/nature/current_issue.html)

*Editorial* | 13 May 2020

### **[Coronavirus drugs trials must get bigger and more collaborative](#)**

The pandemic has given rise to too many small and uncontrolled clinical trials

## **Nature Biotechnology**

Volume 38 Issue 5, May 2020

<https://www.nature.com/nbt/volumes/38/issues/5>

*Editorial* / 05 May 2020

### **[All that's fit to preprint](#)**

COVID-19 has reinforced the importance of preprints as an indispensable means for rapid research dissemination.

*News Feature* | 20 March 2020

### **[The pandemic pipeline](#)**

Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.

John Hodgson

*Comment* / 21 April 2020

### **[Developing therapeutic monoclonal antibodies at pandemic pace](#)**

The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months.

Brian Kelley

*Patents* | 11 May 2020

### **[Adapting the ordre public and morality exclusion of European patent law to accommodate emerging technologies](#)**

Patent law's existing public policy exclusion should be reinterpreted and a new method introduced for assessing the moral and public policy implications of commercializing emerging technologies.

## **Nature Genetics**

Volume 52 Issue 5, May 2020

<https://www.nature.com/ng/volumes/52/issues/5>

[Reviewed earlier]

## **Nature Medicine**



Volume 26 Issue 5, May 2020

<https://www.nature.com/nm/volumes/26/issues/5>

*Comment* | 09 April 2020

**[If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future](#)**

Previous crises have shown how an economic crash has dire consequences for public health. But in the COVID-19 pandemic, the world is entering uncharted territory. The world's leaders must prepare to preserve health.

Martin McKee & David Stuckler

**Nature Reviews Genetics**

Volume 21 Issue 5, May 2020

<https://www.nature.com/nrg/volumes/21/issues/5>

[Reviewed earlier]

**Nature Reviews Immunology**

Volume 20 Issue 5, May 2020

<https://www.nature.com/nri/volumes/20/issues/5>

[Reviewed earlier]

**Nature Reviews Drug Discovery**

Volume 19 Issue 5, May 2020

<https://www.nature.com/nrd/volumes/19/issues/5>

[Reviewed earlier]

**New England Journal of Medicine**

May 14, 2020 Vol. 382 No. 20

<http://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

**[Facing Covid-19 in Italy — Ethics, Logistics, and Therapeutics on the Epidemic's Front Line](#)**

Lisa Rosenbaum, M.D.

**[Novel Coronavirus and Old Lessons — Preparing the Health System for the Pandemic](#)**

J.L. Hick and P.D. Biddinger

**Pediatrics**

Vol. 145, Issue 5 1 May 2020

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

**Pharmaceutics**

Volume 12, Issue 4 (April 2020)  
<https://www.mdpi.com/1999-4923/12/4>  
[Reviewed earlier]

### **PharmacoEconomics**

Volume 38, Issue 5, May 2020  
<https://link.springer.com/journal/40273/38/5>  
[Reviewed earlier]

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>  
(Accessed 16 May 2020)  
[No new digest content identified]

### **PLoS Medicine**

<http://www.plosmedicine.org/>  
(Accessed 16 May 2020)  
[No new digest content identified]

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>  
(Accessed 16 May 2020)  
[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>  
[Accessed 16 May 2020]

#### **[Herd immunity and a vaccination game: An experimental study](https://doi.org/10.1371/journal.pone.0232652)**

Wooyoung Lim, Pengfei Zhang  
Research Article | published 14 May 2020 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0232652>

#### *Abstract*

Would the affected communities voluntarily obtain herd immunity if a cure for COVID-19 was available? This paper experimentally investigates people's vaccination choices in the context of a nonlinear public good game. A "vaccination game" is defined in which costly commitments (vaccination) are required of a fraction of the population to reach the critical level needed for herd immunity, without which defectors are punished by the natural contagion of epidemics. Our experimental implementation of a vaccination game in a controlled laboratory setting reveals that endogenous epidemic punishment is a credible threat, resulting in voluntary vaccination to obtain herd immunity, for which the orthodox principle of positive externalities fails to account. The concave nature of the infection probability plays a key role in facilitating the elimination of an epidemic.

**PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 16 May 2020]

[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States of America**

<http://www.pnas.org/content/early/>

[Accessed 16 May 2020]

[No new digest content identified]

**Prehospital & Disaster Medicine**

Volume 35 - Issue 3 - June 2020

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

**Preventive Medicine**

Volume 134 May 2020

<https://www.sciencedirect.com/journal/preventive-medicine/vol/134/suppl/C>

[Reviewed earlier]

**Proceedings of the Royal Society B**

13 May 2020 Volume 287 Issue 1926

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

**Public Health**

Volume 181 Pages 1-204 (April 2020)

<https://www.sciencedirect.com/journal/public-health/vol/181/suppl/C>

[Reviewed earlier]

**Public Health Ethics**

Volume 12, Issue 3, November 2019

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

**Public Health Reports**

Volume 135 Issue 2, March/April 2020

<https://journals.sagepub.com/toc/phrg/135/2>

[Reviewed earlier]

**Qualitative Health Research**

Volume 30 Issue 6, May 2020

<http://qhr.sagepub.com/content/current>

[Reviewed earlier]

**Research Ethics**

Volume 16 Issue 1-2, January-April 2020

[Reviewed earlier]

**Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 16 May 2020]

[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest articles*

[No new digest content identified]

**Risk Analysis**

Volume 40, Issue 5 Pages: 899-1110 May 2020

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

**Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 16 May 2020]

[No new digest content identified]

**Science**

15 May 2020 Vol 368, Issue 6492

<http://www.sciencemag.org/current.dtl>

*Policy Forum*

**[Policy opportunities to enhance sharing for pandemic research](#)**

By Michelle Rourke, Mark Eccleston-Turner, Alexandra Phelan, Lawrence Gostin

Science 15 May 2020 : 716-718 Full Access

COVID-19 reveals gaps in international law that can inhibit timely sharing of information, samples, and sequences

### **Blockchain-facilitated sharing to advance outbreak R&D**

By Mark B. van der Waal, Carolina dos S. Ribeiro, Moses Ma, George B. Haringhuizen, Eric Claassen, Linda H. M. van de Burgwal

Science15 May 2020 : 719-721 Full Access

Technology may help overcome nontechnological barriers

### *Research Articles*

### **Effective containment explains subexponential growth in recent confirmed COVID-19 cases in China**

By Benjamin F. Maier, Dirk Brockmann

Science15 May 2020 : 742-746 Open Access [CCBY](#)

Feedback between the epidemic process, the behavioral response to it, and nationwide containment policies can restrain COVID-19.

### **Science Translational Medicine**

13 May 2020 Vol 12, Issue 543

<https://stm.sciencemag.org/>

[New issue; No digest content identified]

### **Social Science & Medicine**

Volume 250 April 2020

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/250/suppl/C>

*Research article Open access*

### **Childhood vaccinations and adult schooling attainment: Long-term evidence from India's Universal Immunization Programme**

Arindam Nandi, Santosh Kumar, Anita Shet, David E. Bloom, Ramanan Laxminarayan

Article 112885

*Highlights*

- :: Vaccines could provide a broad range of health and non-health benefits.
- :: We examined the link between childhood vaccination and adult schooling in India.
- :: India's UIP was associated with 0.2–0.3 additional schooling grades.

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 16 May 2020]

[No new digest content identified]

### **Travel Medicine and Infectious Diseases**

Volume 34 March–April 2020

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/34/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 25, Issue 4 Pages: i-iv, 387-505 April 2020  
<https://onlinelibrary.wiley.com/toc/13653156/current>  
[Reviewed earlier]

## **Vaccine**

Volume 38, Issue 22 Pages 3811-3918 (8 May 2020)  
<https://www.sciencedirect.com/journal/vaccine/vol/38/issue/22>  
*Selected Content*

*Research article Abstract only*

### **[Ebola vaccine? Family first! Evidence from using a brief measure on Ebola vaccine demand in a national household survey during the outbreak in Sierra Leone](#)**

Mohamed F. Jalloh, Aaron S. Wallace, Rebecca E. Bunnell, Rosalind J. Carter, ... Helena Nordenstedt  
Pages 3854-3861

*Research article Open access*

### **[Confidence in the National Immunization Program among parents in Sweden 2016 – A cross-sectional survey](#)**

Emma Byström, Ann Lindstrand, Jakob Bergström, Kristian Riesbeck, Adam Roth  
Pages 3909-3917

## **Vaccines — Open Access Journal**

<http://www.mdpi.com/journal/vaccines>  
(Accessed 16 May 2020)

*Open Access Article*

### **[Are the Objectives Proposed by the WHO for Routine Measles Vaccination Coverage and Population Measles Immunity Sufficient to Achieve Measles Elimination from Europe?](#)**

by [Pedro Plans-Rubió](#)

Vaccines 2020, 8(2), 218; <https://doi.org/10.3390/vaccines8020218> - 13 May 2020

Viewed by 139

*Abstract*

Background: The World Health Organization (WHO) proposed two-dose measles vaccination coverage of at least 95% of the population and percentages of measles immunity in the population of 85%–95% in order to achieve measles elimination in Europe. The objectives of this study were: (1) [

## **Value in Health**

May 2020 Volume 23, Issue 5, p527-676  
[https://www.valueinhealthjournal.com/issue/S1098-3015\(20\)X0006-4](https://www.valueinhealthjournal.com/issue/S1098-3015(20)X0006-4)  
*THEMED SECTION: PRECISION MEDICINE*  
[Reviewed earlier]

\*

\*

\*

\*

**From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary**

**Dentistry Journal**

Published: 9 May 2020

*Open Access Article*

**Human Papillomavirus (HPV) Vaccine Knowledge, Awareness and Acceptance among Dental Students and Post-Graduate Dental Residents**

SK Mann, K Kingsley -

Introduction: The recent development of a vaccine that is highly effective against the human papillomavirus (HPV) has been met with widespread clinical and public health professional acceptance. However, social and societal barriers to vaccination may hamper public health efforts to prevent HPV-mediated diseases. Although a few studies have evaluated knowledge or awareness of HPV vaccination among dentists or dental educators, few studies have evaluated the acceptance, knowledge and awareness of HPV vaccination among dental students and post-graduate dental residents. The primary goal of this study is to evaluate survey responses regarding acceptance, knowledge and awareness of HPV vaccination among dental students and post-graduate dental residents.

\* \* \* \*

**Media/Policy Watch**

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

**The Atlantic**

<http://www.theatlantic.com/magazine/>

*Accessed 16 May 2020*

*Politics*

**The Most Remarkable Part of Rick Bright's Testimony**

The whistleblower's claims about the government's lack of COVID-19 preparedness went largely uncontested, even by the president's allies.

Russell Berman May 14, 2020

## **BBC**

<http://www.bbc.co.uk/>

*Accessed 16 May 2020*

### **Coronavirus Sanofi: French drug giant rows back after vaccine storm**

14 May 2020

The French pharmaceutical giant Sanofi has rowed back on an apparent promise to prioritise the US market with any potential Covid-19 vaccine.

Sanofi CEO Paul Hudson sparked a row by saying the US government had "the right to the largest pre-order because it's invested in taking the risk".

French Prime Minister Edouard Philippe responded by saying access for all was "non-negotiable".

Sanofi's chairman has now vowed equal access for everyone...

## **The Economist**

<http://www.economist.com/>

*Accessed 16 May 2020*

[No new, unique, relevant content]

## **Financial Times**

<http://www.ft.com/home/uk>

*Accessed 16 May 2020*

*Coronavirus: free to read*

### **Why vaccine 'nationalism' could slow coronavirus fight |**

Health experts fear US-China tensions could hamper global co-operation and limit poorer nations' access to a treatment

May 14, 2020

### **Any Covid-19 vaccine must be treated as a global public good**

David Pilling

## **Forbes**

<http://www.forbes.com/>

*Accessed 16 May 2020*

May 15, 2020

### **Unveiling Effort To Speed COVID-19 Vaccine, Trump Says, 'Vaccine Or No Vaccine, We're Back'**

Dr. Moncef Slaoui will co-lead the effort with Army General Gustave Perna.

By Matt Perez Forbes Staff

## **Foreign Affairs**

<http://www.foreignaffairs.com/>

*Accessed 16 May 2020*

[No new, unique, relevant content]

## **Foreign Policy**

<http://foreignpolicy.com/>

*Accessed 16 May 2020 |*

### **How the Coronavirus Pandemic Will Permanently Expand Government Powers**



For Part 4 in our series on the world after the pandemic, we asked 10 leading global thinkers for their predictions.

*Analysis /*

James Crabtree, Robert D. Kaplan, Robert Muggah, Kumi Naidoo, Shannon O'Neil, Adam Posen, Kenneth Roth, Bruce Schneier, Stephen M. Walt, Alexandra Wrage

### **If There's a Vaccine, Who Gets It First?**

As researchers around the world race to develop a coronavirus vaccine, questions remain over equitable distribution.

Morning Brief | Audrey Wilson

### **The Guardian**

<http://www.guardiannews.com/>

*Accessed 16 May 2020*

[No new, unique, relevant content]

### **New Yorker**

<http://www.newyorker.com/>

*Accessed 16 May 2020*

*Daily Comment*

### **Rick Bright and the Pandemic Path Not Taken**

The course of the pandemic in this country could have been different; the United States failed, and it didn't have to.

By Amy Davidson Sorkin

May 15, 2020

*Q. & A.*

### **The Danger of Rushing Through Clinical Trials During the Coronavirus Pandemic**

An epidemiologist and expert on clinical trials discusses what makes a good trial, why a pandemic is not the time to speed up the drug-approval process, and the most important fixes for our health-care system.

By Isaac Chotiner

May 14, 2020

### **New York Times**

<http://www.nytimes.com/>

*Accessed 16 May 2020*

*Europe*

### **UK to Invest Up to 93 Million Pounds in New Coronavirus Vaccine Centre**

The British government will invest up to 93 million pounds (\$112 million) to accelerate construction of a new vaccines centre, the Department for Business, Energy and Industrial Strategy said on Saturday.

By Reuters

U.S.

### **Trump Says Considering Making Vaccine Available Free of Charge**

U.S. President Donald Trump said on Friday he was looking at possibly making a coronavirus vaccine available free of charge.

By Reuters

*Europe*

### **Costa Rica Seeks Unity for COVID Fight as WHO Assembly Looms**

Costa Rica's president said Friday that COVID-19 can only be defeated if countries shun nationalism and aren't "selfish," urging access to diagnostics and treatment tools for everyone as a major meeting of the World Health Organization's membership looms next week.

By The Associated Press

*Health*

### **US Begins 'Warp Speed' Vaccine Push as Studies Ramp Up**

President Donald Trump vowed to use "every plane, truck and soldier" to distribute COVID-19 vaccines he hopes will be ready by year's end — even as the country's top scientists gear up for a master experiment to rapidly tell if any really work.

By The Associated Press

### **Washington Post**

<https://www.washingtonpost.com/>

*Accessed 16 May 2020*

[No new, unique, relevant content]

\*

\*

\*

\*

### **Think Tanks et al**

### **Brookings**

<http://www.brookings.edu/>

*Accessed 16 May 2020*

[No new relevant content]

### **Center for Global Development** [to 16 May 2020]

<http://www.cgdev.org/page/press-center>

*Accessed 16 May 2020*

May 15, 2020

### **More Harm Than Good? The Net Impact of COVID-19 Policies Is What Matters for Health**

This is the first in a series of blogs in which we'll focus on non-COVID-19 excess deaths caused by the response to COVID-19, part of a larger project at CGD to help policymakers minimize the indirect health impacts of the pandemic.

[Damian Walker](#) et al.

May 12, 2020

### **The Indirect Health Effects of COVID-19: Disrupted and Suspended Health Services**

The full impacts of COVID-19 and the restrictions adopted to mitigate the pandemic are yet to be fully revealed. We do not know the number of deaths indirectly related to the novel

coronavirus around the world, and how these may differ from country to country. We are launching an inventory to track the evolving situation.

[Lydia Regan](#) and [Y-Ling Chi](#)

May 11, 2020

### **[How to Make Sure the Market Delivers a COVID-19 Vaccine](#)**

Every country faces the same fundamental challenge in the face of the COVID-19 pandemic. Their economies and societies cannot fully return to “normal” until we have a safe and effective vaccine. And achieving that goal quickly is not easy. We see four big problems.

[Amanda Glassman](#) and [Rachel Silverman](#)

### **CSIS**

<https://www.csis.org/>

*Accessed 16 May 2020*

[No new relevant content]

### **Council on Foreign Relations**

<http://www.cfr.org/>

*Accessed 16 May 2020*

[No new relevant content]

### **Kaiser Family Foundation**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Accessed 16 May 2020*

[No new relevant content]

*	*	*	*
*	*	*	*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

*CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances. CVEP maintains an academic affiliation with the Division of Medical Ethics, NYU School of Medicine, and an operating affiliation with the Vaccine Education Center of Children’s Hospital of Philadelphia [CHOP].*

*Support for this service is provided by the Bill & Melinda Gates Foundation; PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi Pasteur U.S., Takeda, Moderna Therapeutics (list in formation).*

*Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.*

*	*	*	*
*	*	*	*